Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbuterol SCHEMBL29393729 | 1.00 | ADRB2 (0.58) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| Carbuterol SCHEMBL29801619 | 0.99 | TDP1 (0.59) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| Carbuterol SCHEMBL636549 | 0.99 | TDP1 (0.59) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| Carbuterol SCHEMBL1649345 | 0.97 | ADRB2 (0.55) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| Carbuterol SCHEMBL18047896 | 0.86 | ADRB2 (0.45) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| Bitolterol SCHEMBL5886027 | 0.84 | ADRB3 (0.44) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| SCHEMBL4427576 | 0.83 | ADRB3 (0.64) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| SCHEMBL4431856 | 0.82 | ADRB2 (0.65) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| SCHEMBL11815926 | 0.80 | ADRB2 (0.59) | ADRB2HIF1ATSHRCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL11596685 | 0.80 | TDP1 (0.61) | ADRB2HIF1ATSHRCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4171 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057764-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | ASTRAZENECA AB (SE) | 2025-02-20 | — | — | US | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| EP-4452230-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | Astrazeneca AB (SE) | 2024-10-30 | — | — | EP | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20240252440-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | ASTRAZENECA PHARMACEUTICALS LP (US) | 2024-08-01 | — | — | US | claimed |
| US-20240252432-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | ASTRAZENECA PHARMACEUTICALS LP (US) | 2024-08-01 | — | — | US | claimed |
| EP-4366695-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | AstraZeneca Pharmaceuticals LP (US) | 2024-05-15 | — | — | EP | claimed |
| EP-4175619-B1 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | ASTRAZENECA PHARMACEUTICALS LP (US) | 2024-04-10 | — | — | EP | claimed |
| EP-0526862-A1 | Solid pharmaceutical compositions for oral administration with prolonged gastric residence | VECTORPHARMA INTERNATIONAL S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |
| EP-0523537-A1 | Transdermal therapeutic system for the administration of drugs having bronchodilating activity | ZAMBON GROUP S.p.A. (IT) | 1993-01-20 | — | — | EP | claimed |
| WO-1993000058-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0514415-A1 | NOVEL VEHICLE GAS MIXTURES AND THEIR USE IN MEDICAL PREPARATIONS | BOEHRINGER INGELHEIM KG (DE) | 1992-11-25 | — | — | EP | claimed |
| EP-0513099-A1 | NOVEL VEHICLE GASES AND THEIR USE IN MEDICAL PREPARATIONS | BOEHRINGER INGELHEIM KG (DE) | 1992-11-19 | — | — | EP | claimed |
| WO-1991011495-A1 | NOVEL VEHICLE GAS MIXTURES AND THEIR USE IN MEDICAL PREPARATIONS | BOEHRINGER INGELHEIM KG (DE) | 1991-08-08 | — | — | WO | claimed |
| WO-1991011496-A1 | NOVEL VEHICLE GASES AND THEIR USE IN MEDICAL PREPARATIONS | BOEHRINGER INGELHEIM KG (DE) | 1991-08-08 | — | — | WO | claimed |
| EP-0341559-A2 | Synergistic mixtures and their therapeutical use | BOEHRINGER INGELHEIM KG (DE) | 1989-11-15 | — | — | EP | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |